tbuckley/cabot-search huggingface dataset:
Successful prevention of balloon dilatation after complete circumferential endoscopic submucosal dissection including long-segment Barrett’s esophagus
Authors: Kenichiro Okimoto, Tomoaki Matsumura, Keisuke Matsusaka, Yuki Ohta, Takashi Taida, Jun Kato, Naoya Kato
Journal: Endoscopy (2024)

Triamcinolone acetonide (TA) injection into submucosa is useful for prevention of stricture after esophageal endoscopic submucosal dissection (ESD) [1]. However, despite attempts with steroid use, complete circumferential esophageal ESD still leads to high stricture rates (36.4% to 85.7% [2] [3] [4]). Although endoscopic balloon dilatation (EBD) is often necessary for stricture relief, it carries the risk of perforation [2]. In addition, in long-segment Barrett's esophagus (BE) with Barrett's esophageal adenocarcinoma (BEA), post-ESD ulcers can be too long, making EBD challenging. Thus, alternative stricture methods preventing EBD are needed.
Clofazimine enteropathy: a case of pigmentation of the whole small intestine caused by clofazimine
Authors: Huan Zhang, Qinghui Peng, Xinhua Zhao, Yuanjing He, Jun Liu
Journal: Endoscopy (2024)

Clofazimine is mainly used for the treatment of neoplastic leprosy, and can also be used in combination with other anti-tuberculosis drugs to treat multidrug-resistant tuberculosis.
Endoscopic management of long-standing rectovaginal fistula caused by foreign bodies
Authors: Li Wang, Zu-Qiang Liu, Pei-Rong Xu, Lu Yao, Hao Hu, Quan-Lin Li, Ping-Hong Zhou
Journal: Endoscopy (2024)

A 32-year-old woman was admitted, presenting with a 30-year history of rectovaginal fistula (RVF). At the age of 1 year, the patient inadvertently ingested a paperclip, resulting in fecal discharge from the vagina, and no intervention was implemented.
First report of opportunistic screening for nasopharyngeal carcinoma by gastroscopy
Authors: Jialiang Huang, Qinkai Li, Wei Wu
Journal: Endoscopy (2024)

A 45-year-old woman presented at our hospital with epigastric pain. Gastroscopy was undertaken, but before the gastroscope was inserted into her esophagus, her nasopharynx was examined. This examination revealed a 1.8-cm lesion ([Video 1]) near the pharyngeal opening of the eustachian (pharyngotympanic) tube on the right side. Blue light imaging and linked color imaging showed irregular microvasculature on the surface of the lesion ([Fig. 1]). Pathological analysis identified squamous cell nonkeratinized carcinoma, with positive immunohistochemistry for P40 ([Fig. 2] a) and CK5/6 ([Fig. 2] b). The Ki-67 index was 50%. Subsequently, the patient was diagnosed with nasopharyngeal carcinoma. This is the first report of opportunistic screening for nasopharyngeal carcinoma using gastroscopy.
Enhanced disease-specific survival in lentigo maligna melanoma patients treated with Mohs surgery over wide local excision: A retrospective cohort analysis of the Surveillance, Epidemiology, and End Results database
Authors: Mitchell A Taylor, Sierra I Thomas, Jennifer M Fernandez, Megan Wackel, Divya Sharma, Vanessa B Voss, Ashley Wysong
Journal: Journal of the American Academy of Dermatology (2024)
Correction: WESTern outcomes of circumferential Endoscopic submucosal dissection for Oesophageal Squamous cell carcinoma – WESTEROS study
Authors: E. Rodriguez de Santiago, P. Deprez, M. J. Bourke, P. Mathieu, R. E. Pouw, S. Seewald, P. Barreiro, A. Lemmers, K. Ricardo, D. Libanio, H. Uchima, D. de Frutos, H.D. T. Alberto, M. Kaminski, R. Z. Felipe, J. Bergman, P. Adolfo, W. Bas, C. Andreia, D. P. Nastazja, S. Groth, V. Yakovenko, A. R. Franco, G. Sunil, J. Jacques, T. Ponchon, J. Rivory, M. Frederic, J. Santos-Antunes, E. Albéniz, E. Alanna, H. Messmann, T. Wallenhorst, P. Andreas, P. Beatriz, P. Sofía, M. Noor, F. Catarina, A. Myriam, T. Pedro, Y. Vladyslav, A. A. Muhammad, M. M. Ewerton, S. Belkhir, D. R. Mario
Journal: Endoscopy (2023)
Oropouche fever outbreak in Brazil: an emerging concern in Latin America
Authors: Ranjit Sah, Shriyansh Srivastava, Sachin Kumar, Pougang Golmei, Sk Abdul Rahaman, Rachana Mehta, Carolina Ferraz, Vasso Apostolopoulos, Alfonso J Rodriguez-Morales
Journal: The Lancet Microbe (2024)
Systemic lupus erythematosus in Aboriginal and Torres Strait Islander peoples in Australia: addressing disparities and barriers to optimising patient care
Authors: Laura E Eades, Alberta Y Hoi, Ruaidhri Liddle, Jason Sines, Rangi Kandane-Rathnayake, Sachin Khetan, Johannes Nossent, Greta Lindenmayer, Eric F Morand, David F L Liew, Maureen Rischmueller, Stephen Brady, Alex Brown, Fabien B Vincent
Journal: The Lancet Rheumatology (2024)
The impact of urban configuration types on urban heat islands, air pollution, CO2 emissions, and mortality in Europe: a data science approach
Authors: Tamara Iungman, Sasha Khomenko, Evelise Pereira Barboza, Marta Cirach, Karen Gonçalves, Paula Petrone, Thilo Erbertseder, Hannes Taubenböck, Tirthankar Chakraborty, Mark Nieuwenhuijsen
Journal: The Lancet Planetary Health (2024)
First clinical application of a novel duodenal mucosal ablation device for type 2 diabetes using radiofrequency vapor ablation
Authors: Apostolis Papaefthymiou, Benjamin Norton, Pablo Becerra Hoebel, Leonardo Rodriguez Grunert, Rehan J. Haidry
Journal: Endoscopy (2024)

Duodenal mucosal ablation is an emerging endoscopic technique for the management of metabolic diseases, providing promising results for the control of type 2 diabetes [1] [2]. The continuous advancement of endoscopic devices aims to optimize procedural efficacy, operability, and scalability [3].
Ligation-assisted endoscopic full-thickness resection combined with preloaded sutures for tiny mesenchymal tumors of the gastric fundus
Authors: Minna Zhang, Peng Shen, Wenzhuo Zhao, Weijie Dai, Xiaozhong Yang, Rui Xie
Journal: Endoscopy (2024)

Gastrointestinal stromal tumors (GISTs) are the most prevalent tumors of mesenchymal tissue origin in the gastrointestinal tract [1]. Currently, the treatment of small GISTs (≤2 cm) and micro-GISTs (<1 cm) remains controversial. Endoscopic full-thickness resection (EFTR) is indicated for microscopic GISTs originating from the intrinsic muscularis propria, facilitating thorough tumor removal and minimizing the risk of dissemination [2]. The fundus of the stomach is one of the commoner sites for GISTs, and performing EFTR here requires high levels of endoscopic skill and, because of the small size of the tumor, it is very easy for it to fall into the abdominal cavity after the final resection [3]. To overcome this challenge, we used a transparent cap-assisted endoscopic full-thickness ligation (EFTR-L) technique combined with preloaded sutures ([Video 1]), which allowed not only complete tumor resection and rapid specimen recovery, but also the prevention of intraoperative bleeding and perforation by use of the preloaded sutures.
Combined endoscopic management of a postoperative rectocutaneous fistula after cystectomy using modified percutaneous endofistular and transanal endoluminal vacuum therapy
Authors: Ahmed Alwali, Clemens Schafmayer, Imad Kamaleddine
Journal: Endoscopy (2024)

A 79-year-old man presented with a transanal purulent discharge following cystectomy with rectal injury 10 months previously. At that time, surgical closure with suturing of the rectal defect had been performed, along with the creation of a colostomy. Endoscopic examination revealed a perforation 5 cm from the anal verge. An attempt was made to close the perforation with an over-the-scope clip; however, during the follow-up endoscopy, a significant defect was observed in rectum, with an accompanying large cavity. The patient then underwent 6 weeks of inpatient therapy with endoluminal transanal vacuum therapy, which resulted in a reduction of the cavity size. The patient returned to us 4 months later with persistent purulent discharge from the caudal pole of the laparotomy scar and anus ([Fig. 1]). Endoscopic examination revealed a defect in the anterior wall of the rectum 5 cm from the anal verge, with a cavity full of pus and a rectocutaneous fistula. We opted for a combined approach involving endoluminal and endofistular vacuum therapy for 3 weeks in the hospital setting ([Fig. 2]).
Evaluation and validation of a PrintrLab-based LAMP assay to identify Trypanosoma cruzi in newborns in Bolivia: a proof-of-concept study
Authors: Lizeth Rojas Panozo, Silvia Rivera Nina, Diana P Wehrendt, Aina Casellas, Lilian Pinto, Susana Mendez, Chi-Wei Kuo, Daniel F Lozano, Lourdes Ortiz, Maria-Jesus Pinazo, Albert Picado, Sergi Sanz, Marcelo Abril, Joaquim Gascon, Season Wong, Alejandro G Schijman, Faustino Torrico, Julio Alonso-Padilla
Journal: The Lancet Microbe (2024)

BackgroundVertical transmission of Trypanosoma cruzi represents approximately 20% of new Chagas disease cases. Early detection and treatment for women of childbearing age and newborns is a public health priority, but the lack of a simple and reliable diagnostic test remains a major barrier. We aimed to evaluate the performance of a point-of-care loop-mediated isothermal amplification (LAMP) assay for the detection of T cruzi.MethodsIn this proof-of-concept study, we coupled a low-cost 3D printer repurposed for sample preparation and amplification (PrintrLab) to the Eiken T cruzi-LAMP prototype to detect vertically transmitted T cruzi, which we compared with standardised PCR and with the gold-standard algorithm (microscopy at birth and 2 months and serological study several months later). We screened pregnant women from two hospitals in the Bolivian Gran Chaco province, and those who were seropositive for T cruzi were offered the opportunity for their newborns to be enrolled in the study. Newborns were tested by microscopy, LAMP, and PCR at birth and 2 months, and by serology at 8 months.FindingsBetween April 23 and Nov 17, 2018, 986 mothers were screened, among whom 276 were seropositive for T cruzi (28·0% prevalence, 95% CI 25·6–31·2). In total, 224 infants born to 221 seropositive mothers completed 8 months of follow-up. Congenital transmission was detected in nine of the 224 newborns (4·0% prevalence, 1·9–7·5) by direct microscopy observation, and 14 more cases were diagnosed serologically (6·3%, 3·6–10·3), accounting for an overall vertical transmission rate of 10·3% (6·6–15·0; 23 of 224). All microscopy-positive newborns were positive by PrintrLab-LAMP and by PCR, while these techniques respectively detected four and five extra positive cases among the remaining 215 microscopy-negative newborns.InterpretationThe PrintrLab-LAMP yielded a higher sensitivity than microscopy-based analysis. Considering the simpler use and expected lower cost of LAMP compared with PCR, our findings encourage its evaluation in a larger study over a wider geographical area.FundingInter-American Development Bank.
Stemming the rising tide of Vibrio disease
Authors: Craig Baker-Austin, Iain Lake, Elizabeth Archer, Rachel Hartnell, Joaquin Trinanes, Jaime Martinez-Urtaza
Journal: The Lancet Planetary Health (2024)

Globally, the diverse bacterial genus Vibrio is the most important group of bacterial pathogens found in marine and coastal waters. These bacteria can cause an array of human infections via direct exposure to seawater or through the consumption of seafoods grown and cultivated in coastal and estuarine settings. Crucially, we appear to be on the cusp of an alarming global increase in Vibrio disease. A worldwide increase in seafood consumption, the globalisation of the seafood trade, the more frequent use of coastal waters for recreational activities, and climate change all contribute to greatly increased human health risks associated with Vibrio bacteria. Coupled with a population that is increasingly susceptible to more serious infections, we are likely to see a marked increase in both reported cases and fatalities in the near future. In this Personal View, we discuss and frame this important and emerging public health issue, and provide various contemporary case studies to illustrate how the risk profiles of pathogenic Vibrio bacteria have transformed in the past two decades—particularly in response to changing climatological and meteorological drivers such as marine coastal warming and extreme weather events such as heatwaves and storms. We share various approaches to help better understand and manage risks associated with these bacteria, ranging from risk mitigation strategies to enhanced epidemiological monitoring and surveillance approaches.
The emerging syndemic of climate change and non-communicable diseases
Authors: Ruth F Hunter, Leandro Garcia, Selina Dagless, Andy Haines, Tarra Penney, Chloe Clifford Astbury, Stephen Whiting, Kremlin Wickramasinghe, Francesca Racioppi, Gauden Galea, Hans Henri P Kluge
Journal: The Lancet Planetary Health (2024)
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
Authors: Peter Borchmann, Justin Ferdinandus, Gundolf Schneider, Alden Moccia, Richard Greil, Mark Hertzberg, Valdete Schaub, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Mathias Hänel, Urban Novak, Julia Meissner, Andreas Zimmermann, Stephan Mathas, Josée M Zijlstra, Alexander Fosså, Andreas Viardot, Bernd Hertenstein, Sonja Martin, Pratyush Giri, Sebastian Scholl, Max S Topp, Wolfram Jung, Vladan Vucinic, Hans-Joachim Beck, Andrea Kerkhoff, Benjamin Unger, Andreas Rank, Roland Schroers, Christian Meyer zum Büschenfelde, Maike de Wit, Karolin Trautmann-Grill, Peter Kamper, Daniel Molin, Stefanie Kreissl, Helen Kaul, Bastian von Tresckow, Sven Borchmann, Karolin Behringer, Michael Fuchs, Andreas Rosenwald, Wolfram Klapper, Hans-Theodor Eich, Christian Baues, Athanasios Zomas, Michael Hallek, Markus Dietlein, Carsten Kobe, Volker Diehl
Journal: The Lancet (2024)

Intensified systemic chemotherapy has the highest primary cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and potentially life long, persisting toxicities. With the new regimen of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD), we aimed to improve the risk-to-benefit ratio of treatment of advanced-stage, classical Hodgkin lymphoma guided by PET after two cycles.
The inclusion of children and adolescents in tuberculosis diagnostic development and evaluation–a consensus statement
Authors: Else M Bijker, Lyn Horn, Sylvia LaCourse, Emily L MacLean, Ben J Marais, Mark P Nicol, Laura Olbrich, James A Seddon, Jayne S Sutherland, Rinn Song, Heather J Zar, Devan Jaganath
Journal: The Lancet Infectious Diseases (2024)
Planetary Health Research Digest
Authors: Cahal McQuillan
Journal: The Lancet Planetary Health (2024)

It is well known that deforestation can negatively impact human health. Health outcomes are typically affected by the resulting increases in air pollution, alterations in vector-borne disease dispersal, and changes in local climate. These relationships have been well studied and the associations clearly defined. The effect of deforestation on newborn health, however, has received far less attention.
Exploring single-cell RNA sequencing as a decision-making tool in the clinical management of Fuchs’ endothelial corneal dystrophy
Authors: Gink N Yang, Yu B Y Sun, Philip Ke Roberts, Hothri Moka, Min K Sung, Jesse Gardner-Russell, Layal El Wazan, Bridget Toussaint, Satheesh Kumar, Heather Machin, Gregory J Dusting, Geraint J Parfitt, Kathryn Davidson, Elaine W Chong, Karl D Brown, Jose M Polo, Mark Daniell
Journal: Progress in Retinal and Eye Research (2024)
Vat-based photopolymerization 3D printing: From materials to topical and transdermal applications
Authors: Angélica Graça, Sara Bom, Ana M. Martins, Helena M. Ribeiro, Joana Marto
Journal: Asian Journal of Pharmaceutical Sciences (2024)

Three-dimensional (3D) printing is an innovative manufacturing method with the potential to revolutionize topical and transdermal dosage forms. Nowadays, it is established that Vat-based photopolymerization (VP) 3D printing technologies offer superior printing efficiency and versatility compared to other 3D printing technologies available on the market. However, there are some limitations that impair their full application in pharmaceutical contexts, such as the lack of a range of biocompatible materials for topical and transdermal applications. This review article explores all types of VP-based 3D printing and discusses the relevance of implementing this kind of technology. We start with a detailed description of the printing process, focusing on the commercial materials available and lab-made resins proposed by different authors. We also review recent studies in this field, which mainly focus on the fabrication of transdermal devices based on microneedle arrays. In the future, it is expected that the manufacturers of 3D printers invest in modifications to the printing apparatus to allow the simultaneous printing of different resins and/or compound types, which will open frontiers to the personalization of treatment approaches.
Letter-to-editor, “Intracellular Criegee's mechanism-based synergistic ozone therapy mediated by oleogels for cancer treatment” [Journal of Controlled Release, Volume 370, pp. 879–890, (2024), DOI: 10.1016/j.jconrel.2024.05.039]
Authors: Jingsong Lu, Lingyun Zhao
Journal: Journal of Controlled Release (2024)
Health resource utilization expenditures in oncology within a virtual primary cancer survivor care clinic.
Authors: Gregory J. Litton, John Librett, Mark Kosinski, Regina Rendas-Baum, Jessica Gentile
Journal: Journal of Clinical Oncology (2024)

e13785 Background: Unprecedented cancer treatment efficacy has led to high rates of disease sequelae. Lancet recently declared the failure to care for the human dimensions of cancer treatment a "humanitarian crisis." To address this humanitarian crisis, real-world economic evidence can improve patient access to whole person care through insurance reimbursement policies. Methods: We implemented a virtual primary cancer survivor care clinic that follows ASCO and NCCN guidelines for cancer survivors with emphasis on mental health, nutrition, physical activity, and sleep optimization. Our clinic utilizes medical oncologists, physician associates, mental health therapists, registered dietitians, and occupational therapists. Patient reported outcomes (PRO) monitor health status and inform treatment pathways. To reduce test fatigue, we use the SF12 Vitality Enhanced scale (SF12v2). The SF12v2 measures physical functioning, activities of daily living, pain, vitality, social functioning, and mental health. Total medical expenditures (MEs) is the sum of payments for hospital inpatient events, emergency room visits, home care, prescribed medicines, office-based and out-patient visits, and medical equipment. Patient SF12v2 summary scores predict a patient's total MEs. A one-point better physical component summary score and mental component summary score are associated with 2% lower MEs; 3 and 5 point score increases are associated with 10% and 18% lower MEs. Results: Patients were referred from a Utah community oncology clinic, other medical clinics, or self-referred (N=99). The mean patient age was 52 years. 84% were female, 16% were male. At enrollment, 35% had started treatment, 21% were on post treatment aromatase therapy or adjuvant hormonal therapy, 65% were post treatment. Baseline PRO reveal significant disease burden: 82% report poor mental health; 72% report poor physical health; 79% report poor cognitive health; 83% report sleep disorders. For patients who completed at least three PRO measurement time points (n=54): 91% had a positive clinical outcome for mental health; 70% had a positive clinical outcome for physical health; 89% had a positive clinical outcome for cognitive health; 76% had a positive clinical outcome for sleep health. As a result of these extraordinary outcomes, 74% of patients had lower predicted MEs. The average predicted reduction in MEs was 16% with an average annual savings of $1,629.49. Conclusions: Cancer is associated with high disease sequelae and high MEs. We believe this is the first study that reports real-world clinical evidence and predicts MEs for patients enrolled in a virtual primary cancer survivor care clinic. Real-world evidence demonstrates both clinically significant improvements in HRQoL and reductions in patient MEs. These results can inform insurance reimbursement policies, ensuring equitable access to cancer survivor care.
Evidence to support ePRO-based patient care in survivorship for outpatient with advanced upper gastrointestinal cancer.
Authors: Xin Shelley Wang, Shu-En Shen, Mona Kamal, Elizabeth Letona, Charles S. Cleeland
Journal: Journal of Clinical Oncology (2024)

e13789 Background: The patients with advanced upper gastrointestinal (UGI) cancer reported multiple symptom burdens at diagnosis and after failing multiple chemotherapy lines. Assessing the readiness of patient-reported outcome (PRO) parameters to support evidence-based pathways for monitoring and managing outpatients is an unmet clinical need to integrate PRO into routine outpatient care for UGI cancer patients. This study aims to identify the most relevant PRO parameters that represent the high symptom burden and functioning impairment overtime during chemotherapy for advanced UGI cancer. Methods: Eligible UGI adult cancer patients (N=111) for a new line of chemotherapy were enrolled. Multiple symptoms were assessed electronically for 36 weeks, using The M.D. Anderson Symptom Inventory GI module (MDASI-GI). Longitudinal symptoms burden was analyzed using mixed-effect models adjusted for age, sex, performance status (PS) (good vs. poor PS ( ECOG 0-1 vs. 2-4). Results: Patients who contributed with more than baseline PROs were included in the analysis (n=92). Of those patients, 43 were treatment-naïve, and 49 had received prior therapy. The primary tumor sites include esophageal (32%), gastroesophageal junction (GEJ) (25%), or gastric (40%). All patients at baseline reported the following symptoms at a severe level (score ≥7 on a 0-10 MDASI-GI scale): fatigue, lack of appetite, pain, disturbed sleep, drowsy, and inability to eat. There was no significant difference in the composite score of these symptoms overtime, regardless of disease groups or treatment status at baseline. Patients with poor PS reported a statistically significant severe composite score baseline ( P=.04). Patients who stayed longer in the study during their survivorship reported a decreased prevalence of moderate to severe symptoms (score of ≥ 4) from 51% at baseline to 40% at 12 weeks, 34% at 24 weeks, and to 28% at 36 weeks. Over time, treatment naïve patients had more severe numbness/tingling, while previously treated group had more severe distress. Conclusions: This longitudinal prospective study during survivorship in patients undergoing chemotherapy for advanced UGI cancer provides a set of most distressing symptom burdens that need to be monitored as part of outpatient care. These data support establishing symptom management pathways for routine use of ePRO for screening and triage of, and linking those symptoms to toxicities after chemotherapy for UGI cancer patients.